Restrictive endocardial fibroelastosis in a neonate without other cardiac pathology

D J Farrell, J R Skinner

Abstract
A case is presented of constrictive endocardial fibroelastosis without other cardiac abnormality in a newborn infant who was treated successfully by orthotopic heart transplantation.

Endocardial fibroelastosis (EFE) with ventricular constriction is generally associated with other cardiac pathology, most commonly hypoplastic left heart syndrome or ventricular outflow obstruction. When not accompanied by other abnormalities, EFE is usually associated with ventricular dilatation. We present a case of constrictive EFE without other cardiac abnormality in a newborn infant who was successfully treated by orthotopic heart transplantation.

Case report
A six week old male infant born at term and weighing 3.2 kg presented with feeding difficulties and vomiting. On examination there were obvious clinical signs of heart failure but he was not cyanosed while breathing air. There were no dysmorphic features. An echocardiogram revealed concordant venous and arterial connections. There was a very small, poorly contracting left ventricle with a bright and strongly thickened endocardium; the left atrium was hugely dilated (fig 1). The mitral and aortic valves, the ascending aorta, and aortic arch looked normal. There was a very low left ventricular output and the systemic circulation was mostly supplied through a large patent ductus arteriosus.

Over a few days he deteriorated, requiring ventilation and inotropic support. At 7 weeks of age palliative surgery was performed: the left atrium was decompressed by atrial septectomy and pulmonary blood flow regulated by banding of the branch pulmonary arteries. Patency of the arterial duct was maintained by prostaglandin infusion.

At 10 weeks of age he underwent an uneventful orthotopic heart transplantation and at 12 months of age was alive and well.

Pathological findings
The recipient heart was submitted for pathological examination. Macroscopic examination showed a globular heart weighing 36 g com-

Figure 1  Subcostal cross-sectional echocardiographic view of the heart. (LA = left atrium, RA = right atrium, LV = left ventricle). There is gross dilatation of the left atrium. The arrows outline the diminutive left ventricle.
The thickened endocardium was composed of parallel bundles of collagen and elastic fibres and extended into the sinusoids of the underlying myocardium which also showed foci of dystrophic calcification. The myocytes were hypertrophic.

**Discussion**

Endocardial fibroelastosis has been described in association with a variety of cardiac and other abnormalities. However, a proportion of cases without other pathology were formerly classified as "primary EFE". Most of these tended to be of the dilated type and the constrictive form of EFE is usually associated with clinically important left ventricular outflow tract obstruction or other major cardiac malformation.

The aetiology and pathogenesis of all forms of EFE remain obscure. It has been suggested that if the left ventricle is regarded as a modified muscular artery, the changes which occur in EFE are similar to those seen in muscular arteries damaged by hypertension. Clearly, in this patient chronic left ventricular hypertension cannot be the reason and the fact that isolated constrictive EFE can occur supports the suggestion that EFE is not a specific condition but rather the pathological result of many different diseases. In other words, there is no "primary EFE" because all EFE is the end stage of some reactive or inflammatory process in the endocardium or myocardium. Endocardial smooth muscle cells, normally few in number, proliferate and undergo a transition to fibroblasts producing both collagen and elastin. The cause of this smooth muscle cell proliferation is unknown but it may be a reaction to myocarditis or a genetic myocardial defect during fetal or early postnatal life.

We acknowledge the advice and comments of Drs S Hunter and H Bain, and we thank Ms L Parker for typing the manuscript. Dr Skinner was supported by the national heart research fund.